Indian Council for Medical and Research gave approval for the new medicine for Covid 19 has been introduced to the market. The Favipiravir tablets are originated from the febi flu of the company Glanmark has been produced. This company has got approval from the ICMR for producing and for the sales. A sheet contains 34 tablets cost rupees 3500 . Where a single tablet cost rupees 103 . They suggested in the First day to consume 9 tablets and the next 14 days to consume 4 tablets daily . In India it has been given to 11 cities and it cures nearly 80 to 88 percent . Japan , United Arab Emirates countries have already used this medicine.

“It is a significant step in the fight against COVID-19 India. Glenmark is leading the flight. We are not looking it as a business opportunity. The priority is to make the drug available to as many patients and save lives,” said Sujesh Vasudevan, president, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals Limited in a video conference.

“Studies conducted on Favipiravir in Russia, Japan and China point to rapid reduction in viral load, faster fever reduction, faster reduction of chest CT changes and faster clinical recovery,” said Dr Monika Tandon, VP, Head, Clinical Development, Glenmark.

“It is for restricted use. Its use entails responsible medication where every patient must have signed informed consent before start of treatment,” Dr. Tandon said adding that approval was given based on global evidence and the ongoing clinical trial on 150 subjects